According to The Insight Partners' research, the Europe Viral Vector Manufacturing Market was valued at US$ 615.8 Million in 2024 and is expected to reach US$ 2,063.2 Million by 2031, registering a CAGR of 19.1% from 2025 to 2031.
Modular and automated manufacturing platformse and expansion of gene editing technologies are among the critical factors attributed to driving the Europe viral vector manufacturing market growth.
Modular and automated manufacturing platforms represent a transformative approach in viral vector production, addressing many of the traditional bottlenecks associated with gene and cell therapy manufacturing. Conventional viral vector manufacturing typically relies on large, fixed, stainless-steel facilities that are capital-intensive, inflexible, and difficult to scale quickly. In contrast, modular platforms employ pre-fabricated, self-contained units-often referred to as "plug-and-play" or BioNTainer-style systems-that can be rapidly deployed and integrated into existing facilities or new sites. These units are designed for compliance with current Good Manufacturing Practices (cGMP) and can be adapted for multiple vector types, including adeno-associated virus (AAV), lentivirus, and adenovirus, enabling manufacturers to switch between programs with minimal downtime.
Automation further enhances these platforms by incorporating digital process control, robotics, and closed-system operations, which significantly reduce human intervention, minimize contamination risks, and improve reproducibility and batch-to-batch consistency. Single-use bioreactors, integrated purification modules, and automated fill-finish lines allow for high-throughput production at a smaller physical footprint. This approach not only accelerates time-to-clinic for early-stage therapies but also supports commercial-scale production, helping meet the growing demand for viral vectors in oncology, rare disease, and immunotherapy applications.
Beyond efficiency, modular and automated platforms support geographic expansion. For example, biotech firms can establish satellite facilities in emerging markets without the cost and complexity of constructing traditional plants. Regulatory agencies are increasingly receptive to these technologies, acknowledging that automated, closed systems can reduce contamination risk and improve quality assurance.
Overall, the integration of modular and automated manufacturing platforms represents a paradigm shift in viral vector production. It offers flexibility, scalability, and risk mitigation, while enabling faster and more cost-effective delivery of gene and cell therapies. Companies adopting these platforms gain a competitive advantage by addressing supply bottlenecks, improving product consistency, and expanding their capacity to serve global clinical and commercial markets.
On the contrary, the sensitivity to raw material and supply chain fluctuations hampers the growth of the Europe viral vector manufacturing market.
Europe Viral Vector Manufacturing Market Segmentation Analysis:
- By Type, the Europe Viral Vector Manufacturing Market is segmented into Adenoviral Vectors, Adeno-Associated Viral Vectors, Lentiviral Vectors, Retroviral Vectors, and Others. The Adenoviral Vectors segment is projected to expand at a CAGR of 18.6% during 2025 - 2031.
- By Disease Indication, the Europe Viral Vector Manufacturing Market is segmented into Cancer, Genetic Disorders, Infectious Diseases, and Others. The Cancer segment is projected to expand at a CAGR of 19.2% during 2025 - 2031.
- By Application, the Europe Viral Vector Manufacturing Market is segmented into Therapeutics Development, Vaccine Development, and Research. The Therapeutics Development segment is projected to expand at a CAGR of 19.6% during 2025 - 2031.
- By End User, the Europe Viral Vector Manufacturing Market is segmented into Pharmaceutical and Biotechnology Companies, CDMOs and CROs, and Research Institutes. The Pharmaceutical and Biotechnology Companies segment is projected to expand at a CAGR of 19.6% during 2025 - 2031.
By country, the Europe Viral Vector Manufacturing Market is categorized into Germany, the United Kingdom, France, Italy, Spain, and the Rest of Europe. Germany is projected to expand at a CAGR of 19.5% during 2025 - 2031.
Key players operating in the Viral Vector Manufacturing Market are Charles River Laboratories International Inc, Novartis AG, Catalent Inc, Lonza Group AG, Merck KGaA, GenScript Biotech Corporation, Takara Bio Inc, FUJIFILM Holdings Corp, WuXi AppTec Co., Ltd., and Thermo Fisher Scientific Inc., among others.
- In June 2025, Thermo Fisher Scientific announced the opening of a new site in the Netherlands specializing in ambient to cryogenic storage, clinical and commercial packaging, labeling, and distribution, and clinical QP release services. The new current good manufacturing practice (cGMP) facility in Bleiswijk, Netherlands, provides pharma and biopharma customers with tailored, end-to-end support throughout the clinical supply chain for high-value therapies, including cell and gene therapies, biologics, antibodies, and vaccines.
Contact Us
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com